IMNM
Immunome Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 12 ▲ Immunome reported Q1 2026 results: net loss of $53.8M ($-0.48/share)…
- May 28 Barclays initiates
- Jun 5 ▲ 1 insider buy $116.9K at $19.48
- Jun 5 ▼ 1 insider sell $203.8K at $19.41
- Jun 15 ▼ 1 insider sell $1.1M at $18.23
- Jun 25 to Jul 7 ▼ 5 days of insider sells: $9.2M by 3 insiders, avg $22.25
- Aug 4 to Aug 12 ▼ 6 days of insider sells: $5.4M by 2 insiders, avg $25.76
- Sep 11 ▼ 1 insider sell $334.2K at $25.32
- Sep 21 Alliance Global Partners initiates
- Oct 1 Stifel initiates
- Oct 5 ▲ Immunome entered into Amendment No. 4 to its License Agreement with…
- Oct 16 William Blair initiates
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider bought $116.9K at an average $19.48. 6 insiders sold $16.2M. Price is 10% below their cost.
- InstitutionsBULLISH
Q3 2026: 21 added (1 new), 14 trimmed or exited.
- AnalystsBULLISH
21 of 23 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate −$0.569 → −$0.600 over 90 days. 0 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest −6.4% to 16.17M shares. 12.8 days to cover, ≈13.7% of shares.
- TrendRANGE
14% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MORGAN STANLEY | TRIM | $36.3M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $12.3M |
| Candriam S.C.A. | TRIM | $10.6M |
| Nuveen, LLC | ADD | $9.4M |
| FEDERATED HERMES, INC. | DOUBLED | $6.6M |
| Qube Research & Technologies Ltd | TRIM | $6.0M |
| Invesco Ltd. | DOUBLED | $5.6M |
| SEI INVESTMENTS CO | DOUBLED | $4.5M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
23 analystsPrice is below the lowest target. Median implies +104%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 10, 2026 | Stifel MAINTAIN | Hold |
| Nov 10, 2026 | Piper Sandler MAINTAIN | Overweight |
| Oct 27, 2026 | Wedbush REITERATE | Outperform |
| Oct 16, 2026 | William Blair INITIATE | Outperform |
| Oct 1, 2026 | Stifel INITIATE | Hold |
| Sep 21, 2026 | Alliance Global Partners INITIATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Higgins Jack Chief Scientific Officer Sep 11, 2026 | SELL | $334.2K |
Higgins Jack Chief Scientific Officer Sep 11, 2026 | EXERCISE | $24.3K |
Higgins Jack Chief Scientific Officer Sep 11, 2026 | GIFT | 8,800 sh |
Barchas Isaac Director Aug 12, 2026 | SELL | $301.1K |
Barchas Isaac Director Aug 11, 2026 | SELL | $1.6M |
Barchas Isaac Director Aug 10, 2026 | SELL | $264.0K |
Barchas Isaac Director Aug 7, 2026 | SELL | $397.4K |
Barchas Isaac Director Aug 6, 2026 | SELL | $543.1K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.60 | -$0.71–-$0.41 | -1.9% | $0.00 |
| Next Q | -$0.74 | -$0.90–-$0.58 | -8.7% | $0.00 |
| Current FY | -$2.50 | -$2.95–-$2.12 | -9.3% | $0.00 |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
20 filings · 5 bullish · 3 bearish · 2 mixed · 10 neutral- NEUTRAL SC 13GNov 16, 2026
Wellington Management Group LLP disclosed a 5.3% passive stake in Immunome Inc. as of September 30, 2026, holding 6,041,333 shares. This is a new SC 13G filing, indicating Wellington crossed the 5% threshold for the first time.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL S-3ASRNov 9, 2026
Immunome filed an automatic shelf registration (S-3ASR) as a well-known seasoned issuer, including…
The shelf filing itself is not an immediate dilutive event. Monitor subsequent prospectus supplements and ATM sales disclosures for actual share issuance. The concurrent 10-Q shows adequate cash…
- NEUTRAL S-3ASRNov 9, 2026
Immunome filed an automatic shelf registration statement (S-3ASR) to register 4,425,487 shares of…
Monitor for any prospectus supplement indicating the timing and method of BMS's resale. The overhang is modest at 3.7% of shares outstanding, but BMS has no standstill restrictions and may sell at…
- BEARISH 8-KNov 9, 2026
Cash and securities totaled $461.6M, down from $582.7M at Q1 end, with cash runway into 2028. Key…
The wider-than-expected loss and accelerating cash burn are the headline negatives, but the varegacestat PDUFA date and EMA validation are key regulatory catalysts. Watch for ASH data on IM-1021 on…
All IMNM filing & press-release reports (20)
- SC 13G reportNov 16, 2026
- S-3ASR reportNov 9, 2026
- S-3ASR reportNov 9, 2026
- 8-K reportNov 9, 2026
- SC 13G reportOct 30, 2026
- William Blair initiates IMNM at OutperformOct 16, 2026
- 8-K reportOct 5, 2026
- Stifel initiates IMNM at Hold, PT $24 (+11.6%)Oct 1, 2026
- Alliance Global Partners initiates IMNM at Buy, PT $32 (+33%)Sep 21, 2026
- CLUSTER reportAug 12, 2026
- CLUSTER reportAug 10, 2026
- CLUSTER reportJul 9, 2026
- CLUSTER reportJul 7, 2026
- CLUSTER reportJul 7, 2026
- CLUSTER reportJul 2, 2026
- Barclays initiates IMNM to Overweight, PT $36 (+66%)May 28, 2026
- 8-K reportMay 12, 2026
- DEFA14A reportApr 24, 2026
- CLUSTER reportMar 23, 2026
- CLUSTER reportMar 23, 2026